Filing Flows › Emergent BioSolutions (EBS) › Commercial Product sales revenue
Emergent BioSolutions (EBS) Commercial Product sales revenue by quarter
Emergent BioSolutions' Commercial Product sales revenue was $43.5M in Q3 2026 (third quarter 2026), -17% from Q2 2026. Over the last 7 quarters it ranged from $38.4M (Q4 2025) to $74.9M (Q3 2025).
| Quarter | Commercial Product sales revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $43.5M | -17% | -42% |
| Q2 2026 | $52.4M | +22% | -22% |
| Q1 2026 | $42.9M | +12% | -5% |
| Q4 2025 | $38.4M | -49% | — |
| Q3 2025 | $74.9M | +11% | — |
| Q2 2025 | $67.5M | +49% | — |
| Q1 2025 | $45.3M | — | — |
Q3 2026 at a glance
Emergent BioSolutions, Q3 2026: revenue $110M (-52% year over year), operating margin -33.9%, net loss $32.7M, operating cash flow $100M. The chart follows the revenue to costs, profit and cash.
Questions
What is Emergent BioSolutions' Commercial Product sales revenue?
Emergent BioSolutions' Commercial Product sales revenue was $43.5M in Q3 2026 (third quarter 2026), -17% from Q2 2026.
How has Emergent BioSolutions' Commercial Product sales revenue changed?
Over the last 7 quarters it ranged from $38.4M (Q4 2025) to $74.9M (Q3 2025).